Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Prostatic Neoplasms × Pioglitazone × Clear all

Phase

Status

Sponsor Class

OTHER 3 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Diabetes Mellitus 2 Urinary Bladder Neoplasms 1 Prostatic Neoplasms, Castration-Resistant 1 Prostatic Neoplasms 1 Pharmacokinetics of MDV3100 1 Neoplasms 1

Interventions

Prednisone 102 enzalutamide 73 Docetaxel 71 Abiraterone Acetate 67 Leuprolide 47 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 45 abiraterone 36 apalutamide 27 Prednisolone 27 bicalutamide 26 Zoledronic Acid 24 pembrolizumab 22 Goserelin 22 radium Ra 223 dichloride 21 darolutamide 21 Triptorelin Pamoate 17 cabazitaxel 15 Androgen Antagonists 14 sipuleucel-T 13 luprolide acetate gel depot 12 Injections 12 Dexamethasone 12 olaparib 11 gallium 68 PSMA-11 10 Mitoxantrone 10 Pluvicto 9 Ipilimumab 9 Dutasteride 9 Cyclophosphamide 9 relugolix 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00427999 2016-11-21

INV342

Novartis

Phase 2 Completed

67 enrolled 6 charts

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡